Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Intarcia Therapeutics
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of type 2 diabetes ≥ 3 months.
Stable regimen of diet and exercise in combination with a stable treatment of liraglutide ≥1.2 mg/day and metformin ≥1000 mg/day.
HbA1c ≤9.5%.
Stable body weight ≥ 3 months.
Body mass index (BMI) ≥25 to ≤45 kg per meter squared.
Calcitonin \<50 ng/L (50 pg/mL) at the Screening Visit.
You may not be if
History of type 1 diabetes.
Recent use or of anti-diabetic medications other than liraglutide or metformin.
History of significant/severe nausea and/or vomiting due to liraglutide.
Significant symptomatic hyperglycemia.
History or evidence, within the last 6 months prior to the Screening Visit, of myocardial infarction, coronary revascularization (coronary artery bypass grafting or percutaneous coronary intervention), unstable angina, or cerebrovascular accident or stroke.
History or evidence of acute or chronic pancreatitis.
History of liver disease.
History of medullary thyroid cancer or a family or personal history of multiple endocrine neoplasia type 2.
Poor thyroid, liver, or renal function.
Serum creatinine levels \>1.5mg/dL (132 μmol/L) for male patients, or \>1.4 mg/dL (123 μmol/L) for female patients.
Weight loss surgery or requires weight loss medications.
History of malignancy (not including basal or squamous cell carcinoma of the skin with past 5 years).
History of active alcohol or substance abuse.
Treatment with medications that affect GI motility.
History of hypersensitivity to exenatide or liraglutide.
Women that are pregnant, lactating, or planning to become pregnant.
Clareo Health | Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
